Myriad Genetics Inc (MYGN): Next-Year EPS Estimate 146.71%
As of 2026-06-11, Myriad Genetics Inc (MYGN) has a next-year EPS growth estimate of 146.71%.
On 2026-06-02, analyst consensus for MYGN's next-year EPS growth shifted from 157.14% to 146.71% — a negative change of 10.43 percentage points. The revised estimate has been sustained across 8 subsequent trading sessions. Current-year growth is projected at 2.08%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- EPS growth next year
- 146.71%
- EPS growth this year
- 2.08%
- EPS next quarter (est)
- -$0.06
- Last price
- $4.63
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-11 | 146.71% | 2.08% | -$0.06 | $4.63 |
| 2026-06-10 | 146.71% | 2.08% | -$0.06 | $4.43 |
| 2026-06-09 | 146.71% | 2.08% | -$0.06 | $4.54 |
| 2026-06-08 | 146.71% | 2.08% | -$0.06 | $4.39 |
| 2026-06-07 | 146.71% | 2.08% | -$0.06 | $4.57 |
| 2026-06-04 | 146.71% | 2.08% | -$0.06 | $4.69 |
| 2026-06-03 | 146.71% | 2.08% | -$0.06 | $4.40 |
| 2026-06-02 | 146.71% | 2.08% | -$0.06 | $4.31 |
| 2026-06-01 | 157.14% | 3.70% | -$0.06 | $4.28 |
| 2026-05-31 | 157.14% | 3.70% | -$0.06 | $3.97 |
| 2026-05-28 | 157.14% | 3.70% | -$0.06 | $4.22 |
| 2026-05-27 | 157.14% | 3.70% | -$0.06 | $3.93 |
| 2026-05-26 | 157.14% | 3.70% | -$0.06 | $3.85 |
| 2026-05-25 | 157.14% | 3.70% | -$0.06 | $3.82 |
| 2026-05-24 | 157.14% | 3.70% | -$0.06 | $3.82 |
| 2026-05-21 | 157.14% | 3.70% | -$0.06 | $3.91 |
| 2026-05-20 | 157.14% | 3.70% | -$0.06 | $3.81 |
| 2026-05-19 | 157.14% | 3.70% | -$0.06 | $3.55 |
| 2026-05-18 | 157.14% | 3.70% | -$0.06 | $3.65 |
| 2026-05-17 | 157.14% | 3.70% | -$0.06 | $3.58 |
| 2026-05-14 | 166.79% | 3.70% | -$0.05 | $3.62 |
| 2026-05-13 | 140.00% | 5.56% | -$0.04 | $3.81 |
| 2026-05-12 | 144.29% | 3.70% | -$0.04 | $4.07 |
| 2026-05-11 | 127.90% | 14.82% | -$0.04 | $4.21 |
| 2026-05-10 | 127.90% | 14.82% | -$0.04 | $4.29 |
| 2026-05-07 | 139.03% | 3.00% | -$0.03 | $4.09 |
| 2026-05-06 | 189.42% | -15.46% | -$0.02 | $4.11 |
| 2026-05-05 | 231.07% | -21.52% | -$0.07 | $5.03 |
| 2026-05-04 | 274.39% | -41.95% | -$0.07 | $4.94 |
| 2026-05-03 | 274.39% | -41.95% | -$0.07 | $4.80 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Myriad Genetics Inc's next-year EPS growth estimate?▾
As of 2026-06-11, Myriad Genetics Inc (MYGN) has a next-year EPS growth estimate of 146.71%, based on analyst consensus.
When was the latest EPS estimate revision for MYGN?▾
The most recent revision occurred on 2026-06-02, when analysts adjusted the next-year EPS growth estimate from 157.14% to 146.71%.
What sector and industry does Myriad Genetics Inc belong to?▾
Myriad Genetics Inc operates in the Healthcare sector, specifically the Diagnostics & Research industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MYGN appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Myriad Genetics Inc (MYGN) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports